MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ehjci/jeag170

Медицинская библиотека · European heart journal. Cardiovascular Imaging · 2026

Incremental prognostic value of cardiac magnetic resonance beyond biomarker staging in transthyretin cardiac amyloidosis.

Chiou Tommy, Minga Iva, Subashchandran Varun, Singulane Cristiane C, Patel Amit R, Zareba Karolina M, Lu Edwin, Goyal Akash, Singh Jai, Elliott Michael D, Nadig Vidya, Fernandes Fabio, Vieira Marcelo L, Fadl Shaimaa, Trankle Cory, Shah Dipan J, Gabr El-Moatasem, Poonawalla Maria, Miralles Franklin, Sarswat Nitasha, Pursnani Amit, Patel Hena, Addetia Karima, Slivnick Jeremy

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

AIMS: While cardiac magnetic resonance (CMR) provides prognostic value in transthyretin cardiac amyloidosis (ATTR-CA), current ATTR-CA staging relies on serum biomarkers. We evaluated the incremental value of incorporating CMR parameters into the National Amyloidosis Centre (NAC) staging and assessed their utility in guiding evaluation for advanced heart failure (HF) therapies and emerging disease-modifying treatments.

METHODS AND

RESULTS

We retrospectively analyzed a multicentre cohort of 266 ATTR-CA patients who underwent CMR between 2007 and 2023. Cox regressions were used to assess time to death. A baseline model was constructed using the NAC stage. CMR predictor variables were selected a priori based on clinical relevance and non-collinearity, then refined using stepwise backward elimination regression with NAC stage control; variables retained in ≥ 60% of 1000 bootstrapped samples were included. Internal validation was performed via bootstrapping, with performance reported as Harrell's C-statistic and calibration slope. Decision curve analysis evaluated clinical utility. A total of 85 patients (32%) died over a median follow-up of 20 months (IQR 8-35). Extracellular volume (ECV ≥ 59%, HR 2.45, 95% CI 1.2-5.2, P = 0.020) and indexed left atrial volume (LAVi ≥ 54 mL/m2, HR 2.00, 95% CI 1.1-3.7, P = 0.026) were independently associated with mortality after NAC adjustment and improved prognostic accuracy across all biomarker stages. When risk prediction was framed around initiation of advanced HF or emerging disease-modifying therapies, incorporating CMR alongside NAC staging facilitated identification of 28 additional high-risk patients per 1000.

CONCLUSION

CMR-derived ECV and LAVi were associated with incremental prognostic value in ATTR-CA beyond biomarker staging and may inform clinical risk stratification.

Для цитирования: Chiou Tommy, Minga Iva, Subashchandran Varun, Singulane Cristiane C, Patel Amit R, Zareba Karolina M, Lu Edwin, Goyal Akash, Singh Jai, Elliott Michael D, Nadig Vidya, Fernandes Fabio, Vieira Marcelo L, Fadl Shaimaa, Trankle Cory, Shah Dipan J, Gabr El-Moatasem, Poonawalla Maria, Miralles Franklin, Sarswat Nitasha, Pursnani Amit, Patel Hena, Addetia Karima, Slivnick Jeremy. Incremental prognostic value of cardiac magnetic resonance beyond biomarker staging in transthyretin cardiac amyloidosis.. European heart journal. Cardiovascular Imaging. 2026. DOI: 10.1093/ehjci/jeag170.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.